Quick Read
- Robbie Williams says his vision is worsening, attributing it to weight-loss jabs, specifically Mounjaro.
- He continues to use the medication, citing improved mental health, but warns fans to research potential risks.
- Medical experts note that a link between these jabs and vision loss is not proven, though some studies suggest increased risk.
- Manufacturer Eli Lilly stresses patient safety and advises consultation with healthcare professionals.
Robbie Williams Speaks Out: Are Skinny Jabs Costing Him His Sight?
Robbie Williams, known to millions for his chart-topping hits and magnetic stage presence, has never shied away from sharing the highs and lows of his personal journey. But in late 2025, his candor took a new turn as he revealed a deeply personal struggle: deteriorating vision, which he believes is linked to the weight-loss medication Mounjaro.
Blurry Vision and Growing Concerns
In interviews with The Sun and reported by LBC, Williams described his experience as both baffling and alarming. “I was quite an early adapter of the jabs, but what I’m also noticing is that my eyesight’s not very good,” he admitted. The singer, now 51, says his vision has grown increasingly blurry over the past months, affecting both his daily life and performances. “It’s been blurry for a while now, and it’s only getting worse. I don’t believe it’s age; I believe it’s the jabs.”
Williams recounted a moment at an American football game where the players appeared as indistinct blobs on the field, and described his difficulty seeing fans during his signature ‘She’s The One’ serenades. “I was looking in the direction of these women looking up at me, having this experience that’s quite obviously incredible to them, and little do they know I can’t see them.” He has since visited an optician, though initially didn’t mention Mounjaro as a possible factor. “Of course it’s worrying and by being honest today, obviously I want to warn people reading this of the potential risks, to make sure they do their research.”
Mounjaro’s Manufacturer Responds
Mounjaro, a brand name for tirzepatide produced by Eli Lilly, rose to prominence as a weight-loss aid in addition to its use for type 2 diabetes. Williams is far from alone in his pursuit of weight management through medication: reports indicate nearly 2.5 million purchases of similar ‘skinny jabs’ in July 2025 alone, preceding a price hike.
Eli Lilly responded to the claims, emphasizing: “Patient safety is our top priority. We have ongoing discussions with regulators regarding potential safety and will continue to review data, including any regarding ophthalmic issues. If anyone is experiencing side-effects when taking a Lilly medicine, they should talk to their doctor or healthcare professional.” (LBC)
While Williams’ account has ignited concern, medical experts caution that the evidence linking Mounjaro to vision problems remains inconclusive. Michael Burdon, a consultant at the Royal College of Ophthalmologists, noted, “There are reports saying some patients have a problem with blood flow to the back of the eye, a condition we call NAION (non-arteritic anterior ischemic optic neuropathy). The trouble is, there are so many people taking this drug and it’s not an uncommon condition, so it’s difficult to tell what is the cause.”
Recent studies in the US found patients using certain diabetes medications were up to four times more likely to develop NAION, but consensus on causality or risk magnitude is lacking. Burdon adds, “Then we have to question if the risk is worse than the impact of being significantly overweight. People taking this drug should definitely be supervised by someone who knows what they’re doing — and shouldn’t be buying it over the counter for all sorts of reasons.”
Balancing Physical and Mental Health
Despite the uncertainty, Williams says he is unlikely to stop the medication soon, citing profound improvements in his mental health. “The lack of mental anguish that I’ve felt since I’ve been on Mounjaro is completely and utterly liberating,” he shared. For years, Williams has been open about his battles with intrusive thoughts and depression. Now, he says, “In the last ten years, the clouds have cleared, and I’m a different person.”
This new outlook has translated into a disciplined fitness regimen. “Every morning I get up and do some mobility stuff on my back. Then I do a hundred dips, 200 press-ups, 100 squats every day and just loads of core stuff. Now I want to be able to do pull-ups.” He’s even considering a facelift next year, a testament to his renewed focus on self-care.
Still, Williams remains candid about the trade-offs. “But seriously, I’m that sick I’d probably stay on it until the sight in one eye has completely gone.” For now, he urges fans and fellow patients to do their homework and consult healthcare professionals before starting or continuing similar treatments.
Public Health, Celebrity Influence, and Ongoing Debate
Williams’ openness has sparked widespread debate about the safety of popular weight-loss drugs, especially as their use continues to surge. For millions struggling with obesity or diabetes, medications like Mounjaro offer hope and tangible results. Yet, as Williams’ story illustrates, the quest for wellness can come with unforeseen risks.
Regulatory agencies, manufacturers, and independent researchers continue to examine the data. For now, the advice is clear: medical supervision is essential, and patients must remain vigilant for any side effects, especially those as serious as vision changes.
As the discussion evolves, Williams’ experience stands as a reminder that health choices, even those endorsed by celebrities, demand careful consideration and personal responsibility.
Robbie Williams’ frank testimony highlights the complex intersection between medical innovation, celebrity influence, and patient safety. His willingness to share both the benefits and risks of his treatment challenges fans and the broader public to weigh personal health decisions with informed caution.